scholarly journals Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types

2006 ◽  
Vol 19 (9) ◽  
pp. 1149-1156 ◽  
Author(s):  
Huamin Wang ◽  
Daniel G Rosen ◽  
Hua Wang ◽  
Gregory N Fuller ◽  
Wei Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Histologic Types

scholarly journals The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-15
Author(s):  
Ruoyi Zheng ◽  
Wenming Chen ◽  
Weiting Xia ◽  
Jingyu Zheng ◽  
Qing Zhou
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Protein Expression ◽  
Mrna Expression ◽  
Binding Protein ◽  
Progression Free Survival ◽  
Prognostic Impact ◽  
Mrna Levels ◽  
Insulin Like Growth Factor ◽  
Factor Binding

Purpose. To assess the expression of insulin-like growth factor binding protein (IGFBP) family and its prognostic impact in ovarian cancer (OC) patients. Materials and Methods. The mRNA expression and protein expression of individual IGFBPs in healthy ovarian samples and OC tissues were explored through Oncomine, Gene Expression Profiling Interactive Analysis, and Human Protein Atlas database. Additionally, the prognostic values of the six IGFBP members in patients with OC were evaluated by Kaplan-Meier plotter. Results. IGFBP2 and IGFBP4 mRNA expression were remarkably upregulated in patients with OC. To be specific, the mRNA expression of IGFBP2 was upregulated in patients with serous ovarian cancer (SOC), while IGFBP1/3/4/5/6 mRNA levels were downregulated. In addition, the IGFBP4 protein expression was upregulated in SOC, and the IGFBP6 protein expression was upregulated in both of SOC and endometrioid ovarian cancer (EOC) tissues. High IGFBP1 mRNA levels showed favorable overall survival (OS) and progression-free survival (PFS) in all OC. Meanwhile, increased IGFBP5/6 mRNA levels revealed worsen OS and PFS in all OC patients. IGFBP4/6 mRNA levels predicted unfavorable OS and PFS only in SOC patients. Moreover, the aberrant mRNA expression of IGFBP1/2/4/5/6 was correlated with significantly prognosis in patients receiving different chemotherapeutic regimens. Conclusion. This study indicates that the IGFBP family reveals distinct prognosis in patients with OC. IGFBP1/2/4/5/6 are useful prognostic predictors for chemotherapeutic effect in OC patients, and IGFBP2/4 are potential tumor markers for the diagnosis of OC.

Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5542-5542
Author(s):  
John Ben Liao ◽  
Denise Cecil ◽  
Yushe Dang ◽  
Kelsey K. Baker ◽  
Kelsie J Ovenell ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Binding Protein ◽  
Advanced Ovarian Cancer ◽  
Insulin Like Growth Factor ◽  
Factor Binding

Diagnostic accuracy of serum insulin-like growth factor-binding protein 2 for ovarian cancer

2020 ◽  
Vol 30 (11) ◽  
pp. 1762-1767
Author(s):  
Pande Kadek Aditya Prayudi ◽  
I Nyoman Gede Budiana ◽  
Putu Doster Mahayasa ◽  
I Gede Ngurah Harry Wijaya Surya ◽  
Anak Agung Gede Putra Wiradnyana ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Diagnostic Accuracy ◽  
Roc Curve ◽  
Predictive Value ◽  
Binding Protein ◽  
Threshold Value ◽  
Optimal Threshold ◽  
Insulin Like Growth Factor ◽  
Factor Binding

IntroductionInsulin-like growth factor-binding protein 2 (IGFBP2) plays an important role in the pathogenesis of ovarian cancer. The most prominent effects of IGFBP2 include promoting proliferation, driving invasion, and suppressing apoptosis. This study aimed to determine the diagnostic accuracy of serum IGFBP2 in differentiating between benign and malignant ovarian neoplasms.MethodsPreoperative serum IGFBP2 level was evaluated from 76 women with primary ovarian tumor who underwent exploratory laparotomy at Sanglah General Hospital, Denpasar, Bali, Indonesia. The optimal threshold value of IGFBP2 for the diagnosis of ovarian cancer was determined from the receiver 0perating characteristic (ROC) curve. The diagnosis was confirmed by histopathologic analysis of resected ovarian specimens.ResultsForty-six (60.5%) patients were diagnosed with ovarian cancer. The area under the ROC curve (AUC) of IGFBP2 in detecting ovarian cancer was 0.815 (95% CI: 0.721 to 0.910, P<0.001). For a given specificity larger than 95%, the optimal sensitivity was 63%. The optimal threshold value of IGFBP2 for the diagnosis of ovarian cancer was 804 ng/mL [sensitivity 63%, specificity 96.7%, positive predictive value (PPV) 96.7%, negative predictive value (NPV) 63%, accuracy 76.3%, and diagnostic odd ratio (DOR) 49.5 (95% CI 6.1 to 396.5)]. In a subgroup analysis, IGFBP2 showed excellence performance in diagnosing advanced ovarian cancer (AUC 0.904 [95% CI: 0.806 to 1.000], sensitivity 83.3%, specificity 96.7%, PPV 95.2%, NPV 87.9%, accuracy 90.7%, and DOR 145.0 [95% CI 15.0 to 1395.3]).ConclusionIGFBP2 is a novel and potentially promising biomarker for detecting ovarian cancer. Further studies are needed to confirm its diagnostic performance in premenopausal women and for detecting early stage ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document